Thrombotic and bleeding complications in four subpopulations of patients with essential thrombocythemia defined by C-Mpl protein expression and PRV-1 mRNA levels

Haematologica

Volumn 90, Issue 6, 2005, Pages 851-853

  Goerttler, Philipp S ^a   März, Edith ^a   Johansson, Peter L ^b   Andreasson, Björn ^b   Kutti, Jack ^b   Moliterno, Alison R ^c   Marchioli, Roberta ^e   Spivak, Jerry L ^c   Pahl, Heike L ^a,d  

^a UNIVERSITY OF FREIBURG   (Germany)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF FREIBURG   (Germany)

^e NONE

Author keywords

c Mpl; Complications; Essential thrombocythemia; PRV 1

Indexed keywords

ACETYLSALICYLIC ACID; BIOLOGICAL MARKER; C MPL PROTEIN; CELL PROTEIN; ERYTHROPOIETIN; MESSENGER RNA; UNCLASSIFIED DRUG;

ADULT; AGED; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD SAMPLING; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE COURSE; DISEASE DURATION; FEMALE; FOLLOW UP; GENE; GENE OVEREXPRESSION; GRANULOCYTE; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HIGH RISK PATIENT; HUMAN; LABORATORY TEST; LEUKOCYTE COUNT; LOGISTIC REGRESSION ANALYSIS; MALE; PREDICTION; PROTEIN EXPRESSION; PRV 1 GENE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; THROMBOCYTE; THROMBOCYTHEMIA; THROMBOEMBOLISM;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HEMORRHAGE; HUMANS; ISOANTIGENS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PROTO-ONCOGENE PROTEINS; RECEPTORS, CELL SURFACE; RECEPTORS, CYTOKINE; RECEPTORS, THROMBOPOIETIN; RETROSPECTIVE STUDIES; RISK; RNA, MESSENGER; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOSIS;

EID: 21244487393     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Barbui T, Barosi G, Grossi A, Gugliotta L, Liberate LN, Marchetti M, et al. Practice guidelines for the therapy of essen-tial thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 2004;89:215-32.
2. Harrison CN, Gale RE, Machin SJ, Linch DC. A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications. Blood 1999;93:417-24.
3. Andreasson B, Harrison C, Lindstedt G, Linch D, Kutti J. Monoclonal myelopoiesis and subnormal erythropoietin concentration are independent risk factors for thromboembolic complications in essential thrombocythemia. Blood 2003; 101:783.
4. Teofili L, Pierconti F, Di Febo A, Maggiano N, Vianelli N, Ascani S, et al. The expression pattern of c-mpl in megakaryocytes correlates with thrombotic risk in essential thrombocythemia. Blood 2002;100:714-7.
5. Johansson P, Kicksten A, Wennstrom L, Palmqvist L, Kutti J, Andreasson B. Increased risk for vascular complications in PRV-1 positive patients with essential thrombocythaemia. Br J Haematol 2003;123:513-6.
6. Griesshammer M, Klippel S, Strunck E, Temerinac S, Mohr U, Heimpel H, et al. PRV-1 mRNA expression discriminates two types of Essential Thrombocythemia. Ann Hematol 2004; 83:364-70.
7. Kralovics R, Buser AS, Teo SS, Coers J, Tichelli A, Van Der Maas AP, et al. Comparison of molecular markers in a cohort of patients with chronic myeloproliferative disorders. Blood 2003;102:1869-71.
8. Moliterno AR, Hankins D, Spivak JL. Impaired expression of the thrombopoietin receptor by platelets from patients with polycythemia vera. N Engl J Med 1998;338:572-80.
9. Klippel S, Strunck E, Temerinac S, Bench AJ, Meinhardt G, Mohr U, et al. Quantification of PRV-1 mRNA distinguishes Polycythemia vera from Secondary Erythrocytosis. Blood 2003;102:3569-74.
10. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.